Myeloid Cytokines for Acute Exposure to Myelosuppressive Doses of Radiation
(Hematopoietic Subsyndrome of ARS)

Print as PDF View/Print as PDF (PDF - 53 KB)

CytokineKey Information
G-CSF: filgrastim
(Neupogen® drug label)
Pegylated G-CSF: pegfilgrastim
(Neulasta® drug label)
G-CSF = granulocyte colony-stimulating factor

Other myeloid colony-stimulating factors (G-CSFs, GM-CSFs)
  • The drugs below are in clinical use for various indications but are NOT approved by the FDA for the specific indication of acute exposure to myelosuppressive doses of radiation.
    • sargramostim (Leukine®) (Sanofi)
    • tbo-filgrastim (Granix®) (Teva)
    • filgrastim-sndz (Zarxio™) (Sandoz/Novartis)
      • Granulocyte colony-stimulating factor (G-CSF)
      • FDA approved filgrastim-sndz (ZARXIO™ Injection, Sandoz Inc.), as biosimilar to US-licensed Neupogen® on March 6, 2015. The date for drug availability in the US has not yet been announced.
      • The formulation of ZARXIO™ differs from that of US-licensed Neupogen® in one inactive component.
      • Drug label for filgrastim-sndz (PDF - 2.9 MB)
General comments:
  • This class of drugs is referred to by various names.
    • Myeloid, white cell, or leukocyte cytokines
    • Myeloid, white cell, or leukocyte growth factors
    • Myeloid, white cell, or leukocyte colony-stimulating factors (CSFs)
  • Specific individual drugs in this class target specific kinds of myeloid cell(s).
    • Neutrophils only (e.g., filgrastim, a G-CSF)
    • Neutrophils and macrophages (e.g. sargramostim, a GM-CSF)
  • Listing on this page does NOT mean that each product is in the U.S. Strategic National Stockpile (SNS).
  • See REMM Exposure Algorithm for the clinical context for using these drugs to treat acute exposure to myelosuppressive doses of radiation (Hematpoietic Subsyndrome of ARS).
Key Clinical Information
  • The goals of using a myeloid colony-stimulating factor for radiation-induced myelosuppression
    • Shorten the duration of severe neutropenia
    • Minimize the severity of neutropenia-associated complications, including infection
    • Improve survival of adults and children exposed to myelosuppressive doses of radiation
  • Initiation of treatment in a radiation incident should be strongly considered for patients who
    • Are likely to have received ≥2 Gy whole body exposure or ≥2 Gy significant partial body exposure
    • Are likely to have an absolute neutrophil count of 500 cells/mm3 or less
    • Will likely have prolonged periods of significant neutropenia (See diagram).
    • Have significant radiation exposure plus trauma and/or burns, which worsens the clinical outcome compared to radiation exposure alone.
  • REMM provides various interactive biodosimetry tools to help estimate the dose of whole body radiation received.
  • Approval of Neupogen® and Neulasta® for acute exposure to myelosuppressive doses of radiation was based on FDA's "Animal Rule".
  • Ethics of using myeloid cytokines for treatment of acute exposure to myelosuppressive doses of radiation
    • No prospective randomized human clinical trials have proven either the efficacy or long- term safety of myeloid growth factors for acute exposure to myelosuppressive doses of radiation
    • Efficacy studies of these drugs could not be conducted in humans with acute radiation syndrome for ethical and feasibility reasons.
    • Approval of this indication was based on efficacy studies conducted in animals and data supporting the use of these drugs for other approved indications.
    • Clinicians should advise patients acutely exposed to myelosuppressive doses of radiation (at risk for the Hematopoietic Subsyndrome of ARS) that efficacy studies of these drugs for this indication could not be conducted in humans for ethical and feasibility reasons and that, therefore, approval of this use was based on efficacy studies conducted in animals.
    • (REMM Note: Considerable clinical experience has been gained worldwide using myeloid cytokines to treat patients after accidental radiation exposure and for various other indications noted on the drug labels.)
Procuring and using myeloid cytokines during large mass casualty incidents
  • Because both Neupogen® and Neulasta® are FDA-approved for the indication of acute exposure to myelosuppressive doses of radiation, neither would require an Emergency Use Authorization (EUA), if used as advised on the drug label for this indication.
  • If there are very significant shortages of medical countermeasures, including myeloid cytokines, senior medical incident managers may recommend modification of standard dosing schedules.
    • Neupogen®: Senior managers might, for example, recommend using Neupogen® at a dose of 5 mcg/kg/day instead of 10 mcg/kg/day, dosing perhaps less frequently than daily until adequate supplies arrive to treat all patients at the higher daily dose, and/or stopping administration when ANC reaches 5,000/mm3 (= 5.0 x 109 cells/L) rather than 10,000/mm3 (= 10.0 x 109 cells/L). These recommendations, however, are NOT included in the FDA drug label.
    • Neulasta®: Senior managers might recommend giving the first dose of Neulasta® (day 1), and require a CBC prior to the second dose (day 8) in order to consider whether the second dose is necessary or possibly delay it. Subject matter experts would recommend NOT administering the second dose if the ANC exceeds 5,000/mm3 (= 5.0 x 109 cells/L). These recommendations, however, are NOT included in the FDA drug label.
  • If resources are scarce, including cytokines, triage modification including when to use cytokines may be considered in order to provide the greatest good for the greatest number of people.
Key safety issues for myeloid cytokines
  • For each drug noted on this page, consult the FDA drug label for detailed information about side effects.
  • Pregnant women: for use of these drugs for acute exposure to myelosuppressive dose of radiation in pregnant women
    • Experts in biodosimetry should be consulted.
    • Any pregnant patient with exposure to radiation should be evaluated by a health physicist and maternal-fetal specialist for an assessment of risk to the fetus.
    • Both Neulasta® and Neupogen® are FDA Pregnancy Category C drugs.
      • This means Risk not ruled out: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
    • Advise females of reproductive potential that Neupogen® or Neulasta® should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
  • Warning and Precautions on the drug label for each product in this category should be noted. Below is a list of serious adverse effects noted on the drug labels. Most are rare. Consult drug labels for more detailed information.
    • Splenic enlargement and rupture
    • Acute Respiratory Distress Syndrome
    • Serious allergic reactions
    • Sickle cell crisis
    • Alveolar hemorrhage and hemoptysis
    • Capillary leak syndrome
    • Thrombocytopenia and Leukocytosis
    • Note: bone pain, which occurs in approximately 25% of patients, is an adverse reaction, but it is not considered "serious".
Clinical Practice Guidelines for Myeloid Cytokines

top of page


References


See: REMM Bibliography for Acute Radiation Injury > Cytokine Section